<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00303784</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000455583</org_study_id>
    <secondary_id>MRC-PATCH</secondary_id>
    <secondary_id>EU-205106</secondary_id>
    <secondary_id>MRC-PR09</secondary_id>
    <secondary_id>ISRCTN70406718</secondary_id>
    <secondary_id>2005-001030-33</secondary_id>
    <nct_id>NCT00303784</nct_id>
  </id_info>
  <brief_title>Prostate Adenocarcinoma TransCutaneous Hormones</brief_title>
  <acronym>PATCH</acronym>
  <official_title>A Randomized-Controlled Trial of Transcutaneous Oestrogen Patches Versus LHRH Agonists in Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: The increasingly prolonged and extended use of androgen deprivation therapy (ADT)&#xD;
      in the treatment of prostate cancer, usually achieved through the administration of LHRH&#xD;
      agonists, has raised concerns about long-term toxicities, in particular osteoporosis and&#xD;
      adverse metabolic changes which may be associated with type II diabetes and increased&#xD;
      cardiovascular risk. An alternative approach is to investigate other methods of ADT. Oral&#xD;
      oestrogen has been shown to be as effective as LHRH and surgical orchidectomy in achieving&#xD;
      castrate levels of testosterone and has equivalent or improved prostate cancer outcomes but&#xD;
      is not used routinely as first-line therapy because of the risk of cardiovascular system&#xD;
      (CVS) complications. The CVS complications have been attributed to first-pass hepatic&#xD;
      metabolism. Administering oestrogen parenterally avoids the entero-hepatic circulation and so&#xD;
      is expected to mitigate the risk of CVS toxicity whilst still effectively suppressing&#xD;
      testosterone to castrate levels. This hypothesis has been supported by results from the early&#xD;
      stages of this trial which have provided sufficient indication of the safety and efficacy of&#xD;
      the patches to warrant further investigation of the treatment in this setting, as recommended&#xD;
      by the IDMC..&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying how well the estrogen skin patch works&#xD;
      compared with luteinizing hormone-releasing hormone agonist injections in treating patients&#xD;
      with locally advanced or metastatic prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the progression-free survival and overall survival of patients with locally&#xD;
           advanced or metastatic prostate cancer treated with transcutaneous estrogen patches vs&#xD;
           luteinizing hormone-releasing hormone analogues.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the cardiovascular system-related morbidity and mortality in patients treated&#xD;
           with these regimens&#xD;
&#xD;
        -  Compare the activity of these treatments, in terms of castrate level of hormones,&#xD;
           failure-free survival, and biochemical failure, in these patients.&#xD;
&#xD;
        -  Compare other toxicities, including osteoporosis, hot flushes, gynecomastia, and anemia,&#xD;
           in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, controlled, multicenter study. Patients are randomized to 1 of&#xD;
      2 treatment arms at 1(control):1 (patch) ratio.&#xD;
&#xD;
        -  Arm I (control): Patients receive luteinizing hormone-releasing hormone agonists as per&#xD;
           local practice in the absence of unacceptable toxicity.&#xD;
&#xD;
        -  Arm II (patch): Patients receive 4 transcutaneous estrogen patches, changing twice&#xD;
           weekly for 4 weeks. Patients' testosterone levels are measured at week 4. Patients whose&#xD;
           testosterone level is &gt; 1.7 nmol/L continue to receive patch as before and have their&#xD;
           testosterone level measured every 2 weeks. Patients whose testosterone level is &lt; 1.7&#xD;
           nmol/L at week 4 or any other point receive 3 transcutaneous estrogen patches changed&#xD;
           twice weekly in the absence of unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline; at weeks 4, 8, and 12; every 3 months for 24 months.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 2200 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2006</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Up to 180 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 180 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hormone activity by castrate levels of hormones</measure>
    <time_frame>Up to 180 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other toxicity</measure>
    <time_frame>Up to 180 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular morbidity</measure>
    <time_frame>Up to 180 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>Up to 180 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>will be measured using patient-completed questionnaires, EORTC QLQ-C30 and PR25 which is prostate specific</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Anemia</condition>
  <condition>Cardiovascular Complications</condition>
  <condition>Hot Flashes</condition>
  <condition>Osteoporosis</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>LHRH agonists</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomised to the control arm will receive continuous treatment with LHRH agonists as per local practice. Treatment should continue for at least 3 years. LHRH antagonists, such as degarelix, are not allowed on the trial. The recommended &quot;anti-flare&quot; medication is bicalutamide and should be prescribed according to local practice. Control arm medication should be obtained from the hospital pharmacy or GP as per local practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oestrogen Patches</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomised to the investigational arm will receive transcutaneous oestrogen patches (100 micrograms/24 hours). Treatment should be planned to continue for at least 3 years. For patients prescribed bicalutamide or flutamide prior to randomisation, this treatment should be discontinued before treatment with the patches can commence (no washout period is needed).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>3.6mg implant, in pre-filled syringe</description>
    <arm_group_label>LHRH agonists</arm_group_label>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.</description>
    <arm_group_label>Oestrogen Patches</arm_group_label>
    <other_name>FemSeven</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Must meet 1 of the following criteria:&#xD;
&#xD;
               -  Newly diagnosed patients with any of the following:&#xD;
&#xD;
                    -  Stage T3 or T4, NX, M0 histologically confirmed prostate adenocarcinoma with&#xD;
                       prostate-specific antigen (PSA) ≥ 20 ng/mL or Gleason score ≥ 6&#xD;
&#xD;
                    -  Any T, N+, M0, or any T, any N, M+ histologically confirmed prostate&#xD;
                       adenocarcinoma&#xD;
&#xD;
                    -  Multiple sclerotic bone metastases with a PSA ≥ 50 ng/mL without&#xD;
                       histological confirmation&#xD;
&#xD;
               -  Patients with histologically confirmed prostate adenocarcinoma previously treated&#xD;
                  with radical surgery or radiotherapy who are currently in relapse with on of the&#xD;
                  following:&#xD;
&#xD;
                    -  PSA ≥ 4 ng/mL and rising with doubling time less than 6 months&#xD;
&#xD;
                    -  PSA ≥ 20 ng/mL&#xD;
&#xD;
          -  Must have written informed consent&#xD;
&#xD;
          -  Intention to treat with long-term androgen-deprivation therapy&#xD;
&#xD;
          -  Normal testosterone level prior to hormonal treatment&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  No other prior or current malignant disease or cardiovascular system disease that is&#xD;
             likely to interfere with study treatment or assessment&#xD;
&#xD;
          -  No cardiovascular disease, including any of the following:&#xD;
&#xD;
               -  History of cerebral ischemia (e.g., stroke or transient ischemic attack) within&#xD;
                  the past 2 years&#xD;
&#xD;
               -  History of deep vein thrombosis or pulmonary embolism confirmed radiologically&#xD;
&#xD;
               -  History of myocardial infarction (MI) within the past 6 months OR MI more than 6&#xD;
                  months ago with evidence of q-wave anterior infarct on ECG&#xD;
&#xD;
                    -  ECHO or MUGA required for patients with history of ischemic heart disease&#xD;
&#xD;
               -  Left Ventricular Ejection Fraction ≤ 40%&#xD;
&#xD;
          -  No condition or situation that could preclude protocol treatment or compliance with&#xD;
             follow-up schedule&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 12 months since prior adjuvant or neoadjuvant hormonal therapy for localized&#xD;
             prostate cancer AND therapy lasted ≤ 12 months in duration&#xD;
&#xD;
          -  No prior systemic therapy for locally advanced or metastatic prostate cancer&#xD;
&#xD;
          -  No concurrent participation in another clinical trial of prostate cancer treatment&#xD;
             that would preclude study therapy or outcome measures&#xD;
&#xD;
          -  Concurrent prophylactic radiotherapy to prevent gynecomastia allowed&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul D. Abel</last_name>
    <role>Study Chair</role>
    <affiliation>Charing Cross Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Burton-upon-Trent</city>
        <state>England</state>
        <zip>DE13 0RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1283-566-333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Patterson, MD</last_name>
      <phone>44-122324-5151 ext. 2523 and 2</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Walsgrave Hospital</name>
      <address>
        <city>Coventry</city>
        <state>England</state>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-24-7660-2020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid Cheshire Hospitals Trust- Leighton Hopsital</name>
      <address>
        <city>Crewe</city>
        <state>England</state>
        <zip>CW1 4QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. P. Logue, MD</last_name>
      <phone>44-1270-255-141</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayday University Hospital</name>
      <address>
        <city>Croydon</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert A. Huddart, MD</last_name>
      <phone>44-20-8401-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derbyshire Royal Infirmary</name>
      <address>
        <city>Derby</city>
        <state>England</state>
        <zip>DE1 2QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1332-347-141 ext. 2407</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>East Yorkshire</city>
        <state>England</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1482-875-875</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <state>England</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise J. Sheehan, MD</last_name>
      <phone>44-1392-411-611</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grantham and District Hospital</name>
      <address>
        <city>Grantham, Lincolnshire</city>
        <state>England</state>
        <zip>NG31 8DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. Daruwala</last_name>
      <phone>44-1476-565-232</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <state>England</state>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Scrase, MD</last_name>
      <phone>44-147-370-4177</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kidderminster Hospital</name>
      <address>
        <city>Kidderminster Worcestershire</city>
        <state>England</state>
        <zip>DY11 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-190-576-0635</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-113-206-6400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Stewart, MD</last_name>
      <phone>44-207-886-1132</phone>
      <email>s.stewart@imperial.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul D. Abel</last_name>
      <phone>44-20-8383-2268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>England</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Beesley</last_name>
      <phone>44-1622-729-000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <state>England</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1642-850-850</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kings Mill Hospital</name>
      <address>
        <city>Nottinghamshire</city>
        <state>England</state>
        <zip>NG17 4JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-162-362-2515</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santhanam Sundar</last_name>
      <phone>44-115-969-1169</phone>
      <email>santhanam.sundar@nuh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>George Eliot Hospital</name>
      <address>
        <city>Nuneaton</city>
        <state>England</state>
        <zip>CV10 7DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-024-7635-1351</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alexandra Healthcare NHS</name>
      <address>
        <city>Redditch, Worcestershire</city>
        <state>England</state>
        <zip>B98 7UB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-015-2750-3030</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hope Hospital</name>
      <address>
        <city>Salford</city>
        <state>England</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noel Clarke</last_name>
      <phone>44-161-206-5568</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scarborough General Hospital</name>
      <address>
        <city>Scarborough</city>
        <state>England</state>
        <zip>YO12 6QL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Robertson</last_name>
      <phone>44-1723-368-111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stepping Hill Hospital</name>
      <address>
        <city>Stockport</city>
        <state>England</state>
        <zip>SK2 7JE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-161-483-1010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hillingdon Hospital</name>
      <address>
        <city>Uxbridge</city>
        <state>England</state>
        <zip>UB8 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvan J. Pope</last_name>
      <phone>44-1895-238-282</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Walsall Manor Hospital</name>
      <address>
        <city>Walsall</city>
        <state>England</state>
        <zip>WS2 9PS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1922-721-172</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Warwick Hospital</name>
      <address>
        <city>Warwick</city>
        <state>England</state>
        <zip>CV34 5BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1926 495-321</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Worthing Hospital</name>
      <address>
        <city>Worthing</city>
        <state>England</state>
        <zip>BN11 2DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Beard</last_name>
      <phone>44-1903-205-111 ext. 5559</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital</name>
      <address>
        <city>Yeovil</city>
        <state>England</state>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Parker</last_name>
      <phone>44-1935-475-122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ayr Hospital</name>
      <address>
        <city>Ayr</city>
        <state>Scotland</state>
        <zip>KA6 6DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1292-610-555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-141-211-2123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Lester, MD</last_name>
      <phone>44-29-2031-6292</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Kynaston</last_name>
      <phone>44-2920-745-094</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ctu.mrc.ac.uk/our_research/research_areas/cancer/studies/patch_pr09/</url>
    <description>Study homepage at the MRC CTU at UCL</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 15, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hot flashes</keyword>
  <keyword>anemia</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>cardiovascular complications</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

